MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco-25-00056

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025

Stereotactic Radiosurgery in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases: A Multi-Institutional, Phase II, Prospective Clinical Trial.

Aizer Ayal A, Tanguturi Shyam K, Shi Diana D, Catalano Paul J, Shin Kee-Young, Ricca Ivy, Johnson Marciana, Benham Grant, Kozono David E, Mak Raymond H, Hertan Lauren, Chipidza Fallon, Krishnan Monica, Pashtan Itai, Peng Luke, Qian Jack M, Shiloh Ron Y, Cagney Daniel N, Sands Jacob, Brown Paul D, Wen Patrick Y, Haas-Kogan Daphne A, Rahman Rifaquat

СтатьяКлиническое исследование II фазыМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

PURPOSE: Stereotactic radiation (SRS/SRT) as opposed to whole-brain radiation (WBRT) represents the standard of care for patients with a limited number of brain metastases given the relatively favorable toxicity profile associated with stereotactic treatment. However, in patients with small cell lung cancer (SCLC), WBRT remains standard because of a lack of prospective data supporting SRS/SRT and concerns related to intracranial progression and neurologic death when WBRT is omitted. We conducted a single-arm, multicenter, phase II trial of SRS/SRT in patients with SCLC and 1-10 brain metastases to assess neurologic death rates relative to historical controls managed with WBRT (ClinicalTrials.gov identifier: NCT03391362).

METHODS

Patients were eligible if they had SCLC or an extrathoracic small cell primary and 1-10 brain metastases. Previous brain-directed radiation including prophylactic cranial irradiation was not permitted. Neurologic death was defined as marked, progressive, radiographic brain progression accompanied by corresponding neurologic symptomatology without systemic disease progression or systemic symptoms of a life-threatening nature. Close imaging-based surveillance of the brain post-SRS/SRT was used.

RESULTS

Between February 2018 and April 2023, 100 patients were enrolled. The median number of brain metastases was 2 (IQR, 1-4; range, 1-10). The median overall survival was 10.2 months; only 22% of patients required salvage WBRT. In total, 20 neurologic deaths were observed, relative to 64 non-neurologic deaths. The neurologic death rate at 1 year was 11.0% (95% CI, 5.8 to 18.1); the historical rate in patients managed with WBRT was 17.5%.

CONCLUSION

Our prospective, multi-institutional study demonstrated low rates of neurologic death when SRS/SRT as opposed to WBRT is used in patients with SCLC and 1-10 brain metastases who are surveilled closely post-treatment, supporting the utility of stereotactic approaches in this population.

Для цитирования: Aizer Ayal A, Tanguturi Shyam K, Shi Diana D, Catalano Paul J, Shin Kee-Young, Ricca Ivy, Johnson Marciana, Benham Grant, Kozono David E, Mak Raymond H, Hertan Lauren, Chipidza Fallon, Krishnan Monica, Pashtan Itai, Peng Luke, Qian Jack M, Shiloh Ron Y, Cagney Daniel N, Sands Jacob, Brown Paul D, Wen Patrick Y, Haas-Kogan Daphne A, Rahman Rifaquat. Stereotactic Radiosurgery in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases: A Multi-Institutional, Phase II, Prospective Clinical Trial.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. DOI: 10.1200/jco-25-00056.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.